Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (1): 59-63.doi: 10.35541/cjd.20210947

• Research Reports • Previous Articles     Next Articles

COVID-19 vaccination status and its impact on psoriatic lesions in patients with psoriasis treated with biologics: a single-center cross-sectional study

Yang Ying1, Guo Qing1, Hou Suchun1, Min Xue1, Tian Jiabin1, Qiao Zhuhui1, Lin Jialin1, Wang Xiaofei2, Wu Lantuya1, Zhang Zhenying1, Li Zhengfeng1, Wang Bin1, Liu Xiaoming1   

  1. 1Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China; 2Medical Health Intelligent （Shenzhen） Co., Ltd., Shenzhen 518000, China
  • Received:2021-12-30 Revised:2022-10-17 Online:2023-01-15 Published:2023-01-03
  • Contact: Liu Xiaoming E-mail:liuxm@hku-szh.org
  • Supported by:
    High Level-Hospital Program, Health Commission of Guangdong Province, China（HKUSZH201906001）; High Level-Hospital Program, The University of Hong Kong-Shenzhen Hospital（HKUSZH201902010）

PDF

419

Abstract: 【Abstract】 Objective To investigate COVID-19 vaccination status and relevant adverse reactions in patients with psoriasis treated with biological agents, and to explore the effect of COVID-19 vaccination on psoriatic lesions. Methods Clinical data were collected from 572 psoriasis patients aged 18 - 60 years, who were registered in the management system of psoriasis patients treated with biological agents in the University of Hong Kong-Shenzhen Hospital from May 2019 to June 2021. The COVID-19 vaccination status was investigated by telephone interviews, and the vaccination-related information was obtained by fixed healthcare workers during a fixed time period according to a predesigned questionnaire. Measurement data were compared between two groups by using t test, and enumeration data were compared by using chi-square test or Fisher′s exact test. Results The COVID-19 vaccination coverage rate was 43.13% （226 cases） among the 524 patients who completed the telephone interview, and was significantly lower in the biological agent treatment group （30.79%, 105/341） than in the traditional drug treatment group （66.12%, 121/183; χ2 = 60.60, P < 0.001）. The main reason for not being vaccinated was patients′ fear of vaccine safety （49.66%, 148/298）, followed by doctors′ not recommending （26.51%, 79/298）. In the biological agent treatment group after vaccination, the exacerbation of psoriatic lesions was more common in patients receiving prolonged-interval treatment （42.86%, 6/14） compared with those receiving regular treatment （4.40%, 4/91; Fisher′s exact test, P < 0.001）. Skin lesions were severely aggravated in two patients after COVID-19 vaccination, who ever experienced allergic reactions and whose skin lesions did not completely subside after the treatment with biological agents. Conclusions The COVID-19 vaccination coverage rate was relatively low in the psoriasis patients treated with biological agents, and no serious adverse reaction was observed after vaccination. Prolonged-interval treatment due to COVID-19 vaccination ran the risk of exacerbation of skin lesions.

Key words: Psoriasis, Biological agents, Coronavirus infections, Viral vaccines, COVID-19, Cross-sectional studies